Sponsor Overview
Explore verified public information about ADC Therapeutics S.A.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Please submit requests to our partner Sobi for patient access to loncastuximab tesirine (lonca) in countries outside of the United States, excluding Greater China, Singapore and Japan, via their portal at: Managed Access Programmes | Sobi”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 1 supporting sources.
Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria If you cannot be treated by currently available drugs, cell therapy, or clinical trials, contact your treating physician to determine if the loncastuximab tesirine EAP is an option. Available Therapies via Single-Patient EA A U.S. EAP for loncastuximab tesirine (ADCT-402) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL).
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.